Pacific Biosciences of California (NASDAQ:PACB) will be releasing its earnings data after the market closes on Monday, February 1st. Analysts expect Pacific Biosciences of California to post earnings of ($0.02) per share for the quarter.

An institutional investor recently bought a new position in Pacific Biosciences of California stock. Russell Frank Co acquired a new position in shares of Pacific Biosciences of California (NASDAQ:PACB) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 88,165 shares of the company’s stock, valued at approximately $1,155,000. Russell Frank Co owned 0.11% of Pacific Biosciences of California as of its most recent SEC filing.

Pacific Biosciences of California (NASDAQ:PACB) opened at 10.26 on Friday. The firm’s market capitalization is $790.44 million. The stock’s 50 day moving average price is $12.03 and its 200 day moving average price is $7.71. Pacific Biosciences of California has a 12 month low of $3.58 and a 12 month high of $14.00.

A number of equities research analysts recently weighed in on the company. Stephens raised Pacific Biosciences of California from an “equal weight” rating to an “overweight” rating and set a $8.00 target price on the stock in a research report on Friday, October 2nd. Piper Jaffray raised Pacific Biosciences of California from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $7.00 to $9.00 in a research report on Friday, October 23rd. JPMorgan Chase & Co. lifted their target price on Pacific Biosciences of California from $7.00 to $8.00 in a research report on Friday, October 23rd. Zacks Investment Research raised Pacific Biosciences of California from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research report on Tuesday, October 27th. Finally, William Blair reissued a “buy” rating on shares of Pacific Biosciences of California in a research report on Friday, October 23rd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Pacific Biosciences of California presently has an average rating of “Buy” and an average target price of $9.58.

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Company’s Single Molecule, Real-Time (NASDAQ:PACB) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

12 Month Chart for NASDAQ:PACB

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.